Cartesian Therapeutics announced the appointment of Dr. Adrian Bot to its Board of Directors.
Dr. Bot, a biopharma executive with extensive experience in immune, cell, gene therapy, and nanomedicines, will join the Science and Technology Committee.
His expertise in CAR T cell therapies and RNA-based precision medicines will benefit Cartesian as it advances its pipeline and explores new opportunities.
Experience in Biopharma
Dr. Adrian Bot has three decades of experience in research and development in the biopharma industry, specializing in immune engineering.
Leadership Roles
He held prominent leadership positions at Capstan Therapeutics, Kite Pharma, and Gilead Company, contributing to the development of CAR T cell therapies.
Research Publications
Dr. Bot has co-authored over 200 peer-reviewed manuscripts, abstracts, and book chapters, showcasing his extensive research contributions.
- The appointment of Dr. Bot brings a wealth of experience and expertise in advancing cell therapies for autoimmune diseases.
- His background in pioneering CAR T cell therapies and RNA-based precision medicines aligns with Cartesian's mission to expand cell therapies into autoimmunity.
The addition of Dr. Adrian Bot to Cartesian Therapeutics' Board of Directors strengthens the company's leadership team and strategic direction in developing innovative cell therapies for autoimmune diseases.